Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4628-4634

  Feldman, Andrew L ^a   Tamarkin, Lawrence ^b   Paciotti, Giulio F ^b   Simpson, Byron W ^b   Linehan, W Marston ^a   Yang, James C ^a   Fogler, William E ^c   Turner, Ewa M ^a   Alexander, H Richard ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CytImmune Sciences Inc   (United States)

^c EntreMed   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOASSAY; KIDNEY NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHENOTYPE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034488630     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Epidemiologic aspects of renal cell cancer
2. Systemic therapy for renal call carcinoma
3. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
4. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma
5. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
6. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
7. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
8. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
9. Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer
10. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
11. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
12. The inhibition of tumor growth by tumor mass
13. Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases
14. Presence of a growth-stimulating factor in serum following primary tumor removal in mice
15. The results of radical nephrectomy for renal cell carcinoma
16. A new method for producing a specific and high titer antibody against glutamate using colloidal gold as a carrier
17. α1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and a homology with type XV collagen
18. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans
19. Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver
20. Bone morphogenetic protein-1: The type I procollagen C-proteinase
21. The generation of endostatin is mediated by elastase
22. Secreted cathepsin L generates endostatin from collagen XVIII
23. Induction of angiogenesis during the transition from hyperplasia to neoplasia
24. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
25. Angiogenesis in cancer, vascular, rheumatoid and other disease
26. Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV
27. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis
28. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
29. Cloning, expression, and in vitro activity of human endostatin
30. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma
31. Progelatinase. A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival
32. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
33. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
34. Vascular endothelial growth factor increases release of gelatinase A and decrease release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
35. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
36. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation